List of drugs in development for neurodegenerative diseases. Update June 2008.
Pogacić
Vanda
V
Corporate Research, Novartis International AG, Basel, Switzerland.
Herrling
Paul
P
D014151:Anti-Anxiety Agents / Q000627:therapeutic use*; D014150:Antipsychotic Agents / Q000627:therapeutic use*; D018491:Dopamine Agonists / Q000627:therapeutic use; D018492:Dopamine Antagonists / Q000627:therapeutic use; D006801:Humans; D019636:Neurodegenerative Diseases / Q000188:drug therapy*; D018697:Nootropic Agents / Q000627:therapeutic use*; D012702:Serotonin Antagonists / Q000627:therapeutic use; D017366:Serotonin Receptor Agonists / Q000627:therapeutic use
D014151:Anti-Anxiety Agents; D014150:Antipsychotic Agents; D018491:Dopamine Agonists; D018492:Dopamine Antagonists; D018697:Nootropic Agents; D012702:Serotonin Antagonists; D017366:Serotonin Receptor Agonists